Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
Total Valuation
Phio Pharmaceuticals has a market cap or net worth of $14.64M. The enterprise value is -$6.39M.
Market Cap$14.64M
Enterprise Value-$6.39M
Share Statistics
Phio Pharmaceuticals has 11,617,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,617,250
Owned by Insiders5.99%
Owned by Institutions0.39%
Financial Efficiency
Phio Pharmaceuticals’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -43.80%.
Return on Equity (ROE)-0.43
Return on Assets (ROA)-0.40
Return on Invested Capital (ROIC)-43.80%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee0.00
Profits Per Employee-1.74M
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Phio Pharmaceuticals is ―. Phio Pharmaceuticals’s PEG ratio is -0.01.
PE Ratio―
PS Ratio0.00
PB Ratio0.31
Price to Fair Value0.31
Price to FCF-0.79
Price to Operating Cash Flow-1.83
PEG Ratio-0.01
Income Statement
In the last 12 months, Phio Pharmaceuticals had revenue of 0.00 and earned -8.70M in profits. Earnings per share was -1.45.
Revenue0.00
Gross Profit-3.00K
Operating Income-9.22M
Pretax Income-8.70M
Net Income-8.70M
EBITDA-9.22M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was -7.98M and capital expenditures -12.00K, giving a free cash flow of -7.99M billion.
Operating Cash Flow-7.98M
Free Cash Flow-7.99M
Free Cash Flow per Share-0.69
Dividends & Yields
Phio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.58
52-Week Price Change-3.82%
50-Day Moving Average1.13
200-Day Moving Average1.73
Relative Strength Index (RSI)55.45
Average Volume (3m)137.46K
Important Dates
Phio Pharmaceuticals upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Phio Pharmaceuticals as a current ratio of 49.37, with Debt / Equity ratio of 0.00%
Current Ratio49.37
Quick Ratio49.37
Debt to Market Cap0.00
Net Debt to EBITDA2.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Phio Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Phio Pharmaceuticals EV to EBITDA ratio is 1.60, with an EV/FCF ratio of 1.85.
EV to Sales0.00
EV to EBITDA1.60
EV to Free Cash Flow1.85
EV to Operating Cash Flow1.85
Balance Sheet
Phio Pharmaceuticals has $21.03M in cash and marketable securities with $0.00 in debt, giving a net cash position of $21.03M billion.
Cash & Marketable Securities$21.03M
Total Debt$0.00
Net Cash$21.03M
Net Cash Per Share$1.81
Tangible Book Value Per Share$3.37
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Phio Pharmaceuticals is $14.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.00
Price Target Upside1076.47% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast83.95%